FDA Brief

Warning letters Food

FDA warning letter to

Molecular BioLife International, Inc.

High riskIssued Apr 15, 2021Posted Jun 22, 2021Office of Human and Animal Foods West Division II

FDA says Molecular BioLife International sold Shark 2 Collagen and Balanced Kollagen as unapproved drugs with disease-treatment claims.

What happened

FDA reviewed www.molecularbiolife.com from March to April 2021 and found that the company takes orders there for Shark 2 Collagen and Balanced Kollagen. The website and linked white papers claimed the products treat or prevent diseases including cancer, arthritis, psoriasis, lupus, and other conditions, making them drugs under the Act.

What FDA found

  1. The company marketed Shark 2 Collagen and Balanced Kollagen with website claims that they cure, treat, or prevent diseases, so FDA treats them as unapproved new drugs.

    FD&C Act sections 201(g)(1)(B), 201(p), 301(d), and 505(a) [21 U.S.C. 321(g)(1)(B), 321(p), 331(d), 355(a)]
  2. The products were offered for diseases that laypeople cannot safely diagnose or treat without a licensed practitioner, so they lacked adequate directions for use and were misbranded.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  3. Specific Shark 2 Collagen claims said shark collagen attacks cancer cells, shrinks tumors, and treats arthritis, psoriasis, lupus, eczema, and other diseases.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  4. Specific Balanced Kollagen claims said oral collagen prevents chronic illness, joint disorders, heart disease, and certain cancers, and eases osteoarthritis and CJD symptoms.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]
  5. Introducing these misbranded drugs into interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, including documentation. If corrective actions cannot be completed in that time, the company must explain the delay and state when it will finish.

Who should pay attention

  • dietary supplement brands and online marketers that make disease claims
  • retailers and distributors selling collagen or joint-health supplements
  • consumers who rely on supplement websites for treatment advice

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk